[{"id":"2bded2d4-47b6-42ef-85b2-a3d47668df11","acronym":"BELINDA","url":"https://clinicaltrials.gov/study/NCT03570892","created_at":"2021-01-18T17:34:21.137Z","updated_at":"2025-02-25T14:39:57.185Z","phase":"Phase 3","brief_title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03570892 - BELINDA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 05/06/2021","primary_completion_date":" 05/06/2021","study_txt":" Completion: 02/14/2026","study_completion_date":" 02/14/2026","last_update_posted":"2025-02-14"},{"id":"71fc84c6-241a-4534-8cc7-be17409b90e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04276870","created_at":"2021-01-18T20:46:13.854Z","updated_at":"2025-02-25T17:30:11.424Z","phase":"Phase 2","brief_title":"Orphan Indications for CD19 Redirected Autologous T Cells","source_id_and_acronym":"NCT04276870","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD19 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • CD19 expression","tags":["CD19 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 03/10/2028","primary_completion_date":" 03/10/2028","study_txt":" Completion: 03/10/2037","study_completion_date":" 03/10/2037","last_update_posted":"2025-01-30"},{"id":"8f688b25-930e-42ca-9a40-fca5c6f5662a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890236","created_at":"2021-05-18T12:01:56.234Z","updated_at":"2025-02-25T15:54:04.644Z","phase":"Phase 1","brief_title":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","source_id_and_acronym":"NCT04890236","lead_sponsor":"Emory University","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 01/13/2022","start_date":" 01/13/2022","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-01-20"},{"id":"f0a201da-f378-4921-aead-597de9839f37","acronym":"REFUEL","url":"https://clinicaltrials.gov/study/NCT05460533","created_at":"2022-07-15T16:05:35.713Z","updated_at":"2025-02-25T15:54:32.296Z","phase":"Phase 2","brief_title":"A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)","source_id_and_acronym":"NCT05460533 - REFUEL","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD19 • IFNG","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 07/12/2022","start_date":" 07/12/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-10-24"},{"id":"dc060c11-ef1a-4e41-b660-edc9c517c35e","acronym":"CASSIOPEIA","url":"https://clinicaltrials.gov/study/NCT03876769","created_at":"2021-01-18T19:06:40.258Z","updated_at":"2024-07-02T16:34:27.333Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","source_id_and_acronym":"NCT03876769 - CASSIOPEIA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 10/19/2027","primary_completion_date":" 10/19/2027","study_txt":" Completion: 10/19/2027","study_completion_date":" 10/19/2027","last_update_posted":"2024-06-11"},{"id":"475a7d05-25ee-4633-ae5e-c6600c4536e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06408194","created_at":"2024-05-11T04:17:51.062Z","updated_at":"2024-07-02T16:35:01.945Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies","source_id_and_acronym":"NCT06408194","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/13/2024","start_date":" 05/13/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-22"},{"id":"81d99580-964a-4d43-9dfd-629d1f93a58c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642626","created_at":"2021-01-18T17:52:54.288Z","updated_at":"2024-07-02T16:35:14.310Z","phase":"","brief_title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","source_id_and_acronym":"NCT03642626","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/18/2018","start_date":" 12/18/2018","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-03-18"},{"id":"8e72eb1e-e98c-4dc8-902a-51141f27ce4b","acronym":"ELIANA","url":"https://clinicaltrials.gov/study/NCT02435849","created_at":"2021-01-18T11:39:44.133Z","updated_at":"2024-07-02T16:35:19.600Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients","source_id_and_acronym":"NCT02435849 - ELIANA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19 • TCF3","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 01/21/2020","primary_completion_date":" 01/21/2020","study_txt":" Completion: 11/17/2022","study_completion_date":" 11/17/2022","last_update_posted":"2024-02-13"},{"id":"70500982-fdb6-4f26-bc62-15198d012f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674175","created_at":"2023-01-06T15:58:48.048Z","updated_at":"2024-07-02T16:35:25.792Z","phase":"Phase 1/2","brief_title":"Co-administration of CART22-65s and huCART19 for B-ALL","source_id_and_acronym":"NCT05674175","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • CART22 • huCART19"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2029","study_completion_date":" 01/15/2029","last_update_posted":"2023-12-19"},{"id":"06f2e6a8-bdd2-4a87-bef8-65924c69c48b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855253","created_at":"2021-04-22T20:53:39.288Z","updated_at":"2024-07-02T16:35:43.683Z","phase":"Phase 1/2","brief_title":"Study of E7777 Prior to Kymriah for R/R DLBCL","source_id_and_acronym":"NCT04855253","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-07-07"},{"id":"adbf85d4-6017-42e2-bd9d-4c11383853d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05037669","created_at":"2021-09-08T14:53:07.125Z","updated_at":"2024-07-02T16:35:45.109Z","phase":"Phase 1","brief_title":"Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma","source_id_and_acronym":"NCT05037669","lead_sponsor":"University of Pennsylvania","biomarkers":" ALK • BCL2 • CD19 • BCL6 • IGH","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • CD19 • BCL6 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2038","study_completion_date":" 01/01/2038","last_update_posted":"2023-06-22"},{"id":"f3ec149f-4ddd-45d0-86f1-c099712c31f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02030847","created_at":"2021-01-18T09:18:39.697Z","updated_at":"2024-07-02T16:35:45.056Z","phase":"Phase 2","brief_title":"Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02030847","lead_sponsor":"University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 04/26/2018","study_completion_date":" 04/26/2018","last_update_posted":"2023-06-22"},{"id":"f08771f8-b6f4-4b7d-8615-1b3859bb108e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04156659","created_at":"2021-01-18T20:15:11.314Z","updated_at":"2024-07-02T16:35:53.677Z","phase":"Phase 2","brief_title":"Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL","source_id_and_acronym":"NCT04156659","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19 • IL6 • IL10","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2023-03-09"},{"id":"c22ad31a-ea07-445c-91ef-2a4df3c634ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04456023","created_at":"2021-01-18T21:25:47.826Z","updated_at":"2024-07-02T16:36:16.299Z","phase":"Phase 2","brief_title":"Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)","source_id_and_acronym":"NCT04456023","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IFNG • IL6 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 09/27/2027","study_completion_date":" 09/27/2027","last_update_posted":"2022-03-01"},{"id":"6600cd58-6837-4fdf-9b33-8ac726eb99ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123939","created_at":"2021-01-18T15:23:35.631Z","updated_at":"2024-07-02T16:36:27.630Z","phase":"Phase 3","brief_title":"Phase III B in Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03123939","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR • CD19 • CD8 • IGH • CD4","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • CD19 • CD8 • IGH • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 10/13/2020","primary_completion_date":" 10/13/2020","study_txt":" Completion: 10/13/2020","study_completion_date":" 10/13/2020","last_update_posted":"2021-07-21"},{"id":"e8c355cb-1b15-4a4b-a723-61c68a73872a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02906371","created_at":"2021-01-18T14:16:24.268Z","updated_at":"2024-07-02T16:36:28.387Z","phase":"Phase 1","brief_title":"Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome","source_id_and_acronym":"NCT02906371","lead_sponsor":"University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • Actemra IV (tocilizumab)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/11/2020","primary_completion_date":" 03/11/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2021-07-02"},{"id":"01dae087-333b-406a-bb25-d932a3240ff0","acronym":"ENSIGN","url":"https://clinicaltrials.gov/study/NCT02228096","created_at":"2021-01-18T10:26:59.439Z","updated_at":"2024-07-02T16:36:38.298Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients","source_id_and_acronym":"NCT02228096 - ENSIGN","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19 • CD8 • IL6 • CD4 • IL2 • CRP","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD8 • IL6 • CD4 • IL2 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 05/29/2018","primary_completion_date":" 05/29/2018","study_txt":" Completion: 05/24/2019","study_completion_date":" 05/24/2019","last_update_posted":"2020-11-23"},{"id":"7d81b61d-7de3-416d-873a-a6ce2a085e4d","acronym":"OBERON","url":"https://clinicaltrials.gov/study/NCT03628053","created_at":"2021-01-18T17:49:12.791Z","updated_at":"2024-07-02T16:36:43.400Z","phase":"Phase 3","brief_title":"Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03628053 - OBERON","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Kymriah (tisagenlecleucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 10/08/2025","primary_completion_date":" 10/08/2025","study_txt":" Completion: 01/07/2026","study_completion_date":" 01/07/2026","last_update_posted":"2020-07-09"},{"id":"9ddb9a0d-6d59-4c87-8a80-95b0e29caad5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02167360","created_at":"2021-01-18T10:05:41.824Z","updated_at":"2024-07-02T16:37:25.712Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CTL019 in Adult ALL Patients","source_id_and_acronym":"NCT02167360","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/11/2017","primary_completion_date":" 01/11/2017","study_txt":"","study_completion_date":"","last_update_posted":"2017-02-14"}]